[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391014":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":49,"responsibleParty":68,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":43,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":43,"enrollmentInfo":84,"targetDuration":43,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":51,"whyStopped":43,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intracanalicular dexamethasone insert group","EXPERIMENTAL","This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.",[13],"Drug: Dexamethasone Ophthalmic Insert",{"label":15,"type":16,"description":17,"interventionNames":18},"Topical steroid drop group","ACTIVE_COMPARATOR","This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.",[19],"Drug: Prednisolone Acetate 1% Oph Susp",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexamethasone Ophthalmic Insert","DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.",[9],[27],"DEXTENZA®",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Prednisolone Acetate 1% Oph Susp","Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.",[15],[33],"PRED FORTE®, OMNIPRED®",[35],{"name":36,"affiliation":37,"role":38},"Katherine Talcott, M.D.","Cole Eye Institute, Cleveland Clinic","PRINCIPAL_INVESTIGATOR",[40,45],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","440 988-4040",null,"talcotk@ccf.org",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":48},"Angela Meador, MHA","216-445-7176","meadora@ccf.org",[50],{"facility":37,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Cleveland","Ohio","44195","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-81.69541,41.4995,{"lat":61,"lon":60},[64],{"name":65,"role":41,"phone":66,"phoneExt":43,"email":67},"Rishi Singh, M.D","216-445-9497","singhr@ccf.org",{"type":38,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Katherine Talcott","Principal Investigator",[72],{"name":73,"class":74},"Ocular Therapeutix, Inc.","INDUSTRY","100391014","phase-4-dextenza-in-the-post-op-management-of-vitreoretinal-surgeries-100391014",false,"NCT04371445","Dextenza in the Post-op Management of Vitreoretinal Surgeries","Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery","Inclusion Criteria:\n\n* Men and women \\>18 years old\n* Planning to undergo vitreoretinal surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.\n\nExclusion Criteria:\n\n* Patients undergoing combined cataract or glaucoma procedure, intraocular lens exchange, scleral buckle, and\u002For implant of a drug delivery system\n* History of complications, trauma, adverse events, disease in nasolacrimal region, including dacryocystitis, canaliculitis in either eye\n* Structural lid abnormalities such as ectropion or entropion in surgical eye\n* Ongoing use of systemic narcotic pain relievers\n* Presence of any intraocular inflammation (cells and flare) in the study eye at screening\u002Fbaseline\n* Pain score greater than \"0\" on the ocular pain assessment in the study eye at screening\u002Fbaseline\n* Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease, including diabetes\n* Other ocular surgeries or procedures during the study period and\u002For 6 months prior\n* Intraoperative complications\n* Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops, IOP at baseline greater than 25, or advanced optic nerve cupping). Patients with glaucoma or ocular hypertension controlled with a single drop can be enrolled.\n* Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication.\n* Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure and during surgery.\n* Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively.\n* Have used topical, ocular, inhaled or systemic steroids within 14 days prior to procedure\n* Are pregnant or nursing\u002Flactating\n* Participation as a subject in any clinical study within the 30 days prior to randomization.\n* Surgeries using 20 gauge or 23 gauge instruments.","ALL","18 Years",{"count":85,"type":86},30,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group.\n\nPatients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.",[92,93,94,95],"Vitreoretinal Surgery","Ocular Inflammation","Post-operative Pain","Post-Operative Inflammation",[97,93,95,94],"dexamethasone insert","2026-02-06",{"date":100,"type":101},"2026-02-10","ACTUAL",{"date":103,"type":101},"2020-06-01",{"date":105,"type":86},"2026-05-01",{"name":5,"class":6},1]